Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when WGRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsWellgistics raises $16.9M via convertible notes with 20% discount, warrants at $7.50
Filed May 29, 2026 · Period ending May 27, 2026 · ~1 min read
Key Changes
-
high
Company issued $21.1M face value convertible notes for $16.9M cash (20% discount), convertible at $1-$6/share initially, with warrants exercisable at $7.50. Full warrant exercise could yield additional $42.8M, though no assurance of cash exercise.
Item 1.01 verify on EDGAR → -
high
Must obtain stockholder approval under Nasdaq rules to issue shares exceeding 19.99% of outstanding stock. Until approved, conversions and warrant exercises are capped, limiting financing flexibility and creating potential overhang.
Item 1.01 verify on EDGAR → -
medium
Used $1.77M of proceeds to repay Marco Capital debt from November 2024, eliminating existing loan obligation and associated guaranty.
Item 1.01 verify on EDGAR → -
medium
Officers, directors, and holders of 1,333,930 shares (majority of outstanding common) agreed to 90-180 day lock-up restrictions, temporarily reducing insider selling pressure.
Item 8.01 view on EDGAR → -
medium
Securities sold in private placement to accredited investors under Section 4(a)(2) and Regulation D exemptions. Registration rights agreement obligates company to register resale shares.
Item 3.02 verify on EDGAR →
Summary
Wellgistics Health completed a $16.9 million private placement financing on May 27, 2026, issuing convertible notes with a steep 20% original issue discount and warrants exercisable at $7.50 per share. The notes convert to common stock at prices between $1-$6 per share or to preferred stock under certain conditions, representing significant potential dilution for existing shareholders.
The company immediately used $1.77 million to retire debt owed to Marco Capital, improving its balance sheet by eliminating a secured obligation. Retail investors should understand that this financing structure creates substantial dilution risk. The company must obtain stockholder approval to issue shares beyond Nasdaq's 19.99% threshold, which caps conversions and warrant exercises until that vote occurs.
If all warrants are exercised for cash at $7.50, the company could receive up to $42.8 million in additional proceeds, though there's no guarantee investors will choose cash exercise over cashless alternatives. The insider lock-up covering a majority of outstanding shares provides temporary stability but expires in 90-180 days. Watch for the timing and outcome of the required stockholder vote, which will determine whether the company can fully utilize this financing structure. Also monitor whether warrant holders exercise for cash at $7.50 or opt for cashless exercise, as this will significantly impact both dilution levels and the company's cash runway.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Company raised $16.9M via convertible notes with 20% discount and warrants, using proceeds to repay $1.77M debt.
Added in current filing · verify on EDGAR →
On May 27, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers convertible promissory notes in the aggregate principal amount of $21,132,812.50 (the “Notes”) and warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the “PIPE Warrants”). The Notes are being issued for an aggregate cash purchase price of $16,906,250, reflecting a 20% original issue discount, before deducting placement agent fees and offering expenses.
The company raised $16.9 million in cash by issuing convertible notes with a face value of $21.1 million, representing a 20% original issue discount. The notes mature in twelve months, bear 0% interest, and convert to common stock at prices ranging from $1.00 to $6.00 per share initially, or to preferred stock after certain conditions are met. Investors also received warrants exercisable at $7.50 per share.
Added in current filing · verify on EDGAR →
In connection with the Offering, certain officers and directors of the Company and stockholders holding a majority of the Company’s outstanding common stock entered into lock-up agreements with the Placement Agent. ... The lock-up press release states that holders of 1,333,930 common shares, representing a majority of the outstanding common shares, entered into the lock-up arrangement
Officers, directors, and holders of 1,333,930 shares (a majority of outstanding common stock) agreed to lock-up restrictions preventing sales for 90-180 days depending on registration statement effectiveness. This temporarily reduces potential selling pressure from insiders.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Wellgistics sold unregistered securities including Notes, PIPE Warrants, Placement Agent Warrants, and Series A Preferred Stock in a private placement.
Added in current filing · verify on EDGAR →
The Notes, the PIPE Warrants, the Placement Agent Warrants, the Series A Preferred Stock issuable upon conversion of the Notes, the shares of Common Stock issuable upon conversion of the Notes and the Series A Preferred Stock, and the shares of Common Stock issuable upon exercise of the Warrants were, or will be, offered and sold in transactions exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on Section 4(a) (2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder.
The company sold multiple types of securities in a private placement to accredited investors without SEC registration. The offering includes convertible notes, warrants, and preferred stock that can convert into common shares, which will dilute existing shareholders. The transaction relied on exemptions for private placements to sophisticated investors.
Added in current filing · verify on EDGAR →
Each Purchaser represented that it is an accredited investor within the meaning of Rule 501(a) of Regulation D and was acquiring the securities for investment purposes and not with a view to distribution in violation of the Securities Act.
All buyers in this offering were required to be accredited investors purchasing for investment, not resale. This limits the immediate liquidity of the securities but also indicates the company raised capital from sophisticated institutional or high-net-worth investors.
Event · Item 7.01 — Regulation FD Disclosure
Company announced financing and debt restructuring transaction, plus majority shareholder lock-up agreement.
Added in current filing · verify on EDGAR →
On May 27, 2026, the Company issued a press release announcing the financing and debt restructuring transaction described above under Item 1.01.
The company disclosed a financing and debt restructuring transaction via press release on May 27, 2026. The 8-K references Item 1.01 for transaction details, but that section is not included in the provided filing excerpt, so specific terms and amounts are not available here.
Added in current filing · verify on EDGAR →
On May 28, 2026, the Company issued a press release announcing that holders of a majority of the Company’s outstanding common stock entered into a lock-up agreement.
Holders of a majority of the company's outstanding common stock entered into a lock-up agreement, announced May 28, 2026. Lock-up agreements typically restrict shareholders from selling their shares for a specified period, which can reduce near-term selling pressure but may signal concerns about stock volatility or dilution from the financing transaction.
Event · Item 9.01 — Financial Statements and Exhibits
Wellgistics Health disclosed a private placement financing involving convertible notes and warrants via securities purchase agreement.
Added in current filing · verify on EDGAR →
Securities Purchase Agreement, dated May 27, 2026, by and among Wellgistics Health, Inc. and the Purchasers party thereto.
The company entered into a securities purchase agreement with investors on May 27, 2026. This agreement governs the sale of convertible promissory notes and warrants to raise capital through a private placement.
Added in current filing · verify on EDGAR →
Form of Convertible Promissory Note.
The company issued convertible promissory notes as part of the financing transaction. These notes can convert into equity, potentially diluting existing shareholders when conversion occurs.
Added in current filing · verify on EDGAR →
Form of PIPE Warrant.
The company issued warrants to investors in the private placement (PIPE). These warrants give holders the right to purchase additional shares at a predetermined price, representing potential future dilution.
Added in current filing · verify on EDGAR →
Registration Rights Agreement, dated May 27, 2026, by and among Wellgistics Health, Inc. and the Purchasers party thereto.
The company granted registration rights to the investors, obligating it to register the resale of shares underlying the convertible notes and warrants. This allows investors to sell their shares publicly once registered.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Placement Agency Agreement, dated May 27, 2026, by and between Wellgistics Health, Inc. and Dawson James Securities, Inc.
The company engaged Dawson James Securities as placement agent for the financing transaction and issued placement agent warrants as compensation. This represents transaction costs and potential additional dilution from the agent warrants.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 29, 2026 · How we verify